ITGAM and acute myeloid leukemia: The induction of CD11b surface marker expression by fluorizoline was dose-dependent (12.1- and 1.5-fold induction in 40 μM fluorizoline-treated U-937 cells (Figure 4A) and 20 μM fluorizoline-treated de novo AML primary samples (Figure 4B), respectively, compared to DMSO-treated cells at 48 hours) and occurred in parallel to cell viability decrease (Figure 4A and 4B).